New Two-Drug attack on Tough-to-Treat cancers enters human testing
NCT ID NCT05951608
Summary
This study is testing a new combination of two drugs, AK127 and AK112, for people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the combination can shrink tumors. It will involve about 216 adults whose cancer has progressed despite other therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 430022, China
Conditions
Explore the condition pages connected to this study.